Lymphoma Clinical Trials

Showing 2021-2040 of 3,379 trials

Study of Decitabine Combined With HAAG Regimen in Newly Diagnosed ETP-ALL/LBL, T/M-MPAL and ALL/LBL With Myeloid or Stem Cell Markers Patients

NCT04446130

The purpose of this study is to evaluate the efficacy and safety of decitabine combined with HAAG regimen in the treatment of newly diagnosed patients with ETP-ALL/LBL, T/M-MPAL and ALL/LBL with myeloid or stem cell markers.

Induction ChemotherapyAcute T-Lymphocytic LeukemiaT-cell Lymphoblastic Lymphoma Leukemia+1 more

The First Affiliated Hospital of Soochow University100 participantsStarted Jan 2019

Suzhou, Jiangsu, China

UNKNOWNPhase 2

Toripalimab Combine With Rituximab for Treatment of Relapsed Refractory CD20 Positive Diffuse Large B-cell Lymphoma

NCT04425824

Exploring the efficacy and safety of Toripalimab with Rituximab for treatment of relapsed refractory CD20 positive diffuse large B-cell lymphoma.

Diffuse Large B-cell LymphomaRituximabToripalimab

Chinese Academy of Medical Sciences20 participantsStarted Jun 2020

Beijing, China

UNKNOWNPhase 1/2

Multi-CAR-T Cells Targeting B Cell Lymphomas

NCT04429438

This study aims to evaluate safety and efficacy of a combination of 4th generation chimeric antigen receptor gene-modified T cells targeting B cell surface molecules including CD19 and alternative CARTs as booster and consolidation treatment for patients with highly resistant B cell lymphomas, including primary mediastinal B cell lymphoma (PMBCL) and BCL involving central nervous system (CNS-BCL). Clinical response and development of a simplified and standardized lentiviral vector and cell production protocol will be investigated. This is a phase I/II trial enrolling patients from multiple clinical centers.

B Cell Lymphoma (BCL)

Shenzhen Geno-Immune Medical Institute11 participantsStarted Jun 2020

Shenzhen, Guangdong, China • Shenzhen, Guangdong, China • Shenzhen, Guangdong, China

Study of Decitabine Combined With HAAG Regimen in Newly Diagnosed ETP-ALL/LBL, T/M-MPAL and ALL/LBL With Myeloid or Stem Cell Markers Patients

Toripalimab Combine With Rituximab for Treatment of Relapsed Refractory CD20 Positive Diffuse Large B-cell Lymphoma

Multi-CAR-T Cells Targeting B Cell Lymphomas

Related Searches

Safety and Effectiveness of EBV-specific Cytotoxic T Cells for the Treatment for EBV Lymphomas or Other EBV-associated Malignancies

Study of GLS-010 Injection in the Treatment of Classical Hodgkin's Lymphoma

Predictive Value of a mRNA Signature and Liquid Biopsy in Diffuse Large B Cell Lymphoma

Atrial Fibrillation in Patients Receiving Ibrutinib

R2-MTX With Lenalidomide Maintenance in Newly-diagnosed PCNSL：a Multicenter Phase Ib/II Stuty

A Study of GC022F CAR-T Cell Immunotherapy for Relapsed or Refractory B- NHL

Reduced Radiation in Patients With Diffuse Large B-cell Lymphoma

Study of Rituximab-HCVAD Alternating With Rituximab-Methotrexate-Cytarabine Versus Standard Rituximab-CHOP Every 21 Days for Patients With Newly Diagnosed High Risk Aggressive B-Cell Non-Hodgkin's Lymphomas in Patients 60 Years Old or Younger

GPED Regimen for Relapsed/Refractory or Advanced ENKTCL

Influence of Psychosocial Distress and Lifetime Trauma Exposure on Traumatic Stress Among Oncology Patients on Clinical Trials

Tumor Registry of Lymphatic Neoplasia

Bioequivalence & Food Effect Study in Patients With Solid Tumor or Hematologic Malignancies

Allogeneic Bone Marrow Transplantation Using Less Intensive Therapy

A Study of YY-20394 in Participants With Relapsed/Refractory Follicular Non-Hodgkin's Lymphoma

Sintilimab and Decitabine for Patients With Relapsed/Refractory or Advanced NK/T-cell Lymphoma

Lenalidomide and Sintilimab for Relapsed/Refractory NK/T-cell Lymphoma

Zevalin-Containing Nonmyeloablative Conditioning for Stem Cell Transplantation (SCT)